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Abstract
The combination therapy of an angiotensin receptor blocker (ARB) with a calcium channel blocker (CCB) or with a diuretic is
favorably recommended for the treatment of hypertension. However, the difference between these two combination
therapies is unclear. The present work was undertaken to examine the possible difference between the two combination
therapies in vascular protection. Salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP) were divided into 6
groups, and they were orally administered (1) vehicle, (2) olmesartan, an ARB, (3) azelnidipine, a CCB, (4)
hydrochlorothiazide, a diuretic, (5) olmesartan combined with azelnidipine, or (6) olmesartan combined with
hydrochlorothiazide. Olmesartan combined with either azelnidipine or hydrochlorothiazide ameliorated vascular endothelial
dysfunction and remodeling in SHRSP more than did monotherapy with either agent. However, despite a comparable blood
pressure lowering effect between the two treatments, azelnidipine enhanced the amelioration of vascular endothelial
dysfunction and remodeling by olmesartan to a greater extent than did hydrochlorothiazide in salt-loaded SHRSP. The
increased enhancement by azelnidipine of olmesartan-induced vascular protection than by hydrochlorothiazide was
associated with a greater amelioration of vascular nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
activation, superoxide, mitogen-activated protein kinase activation, and with a greater activation of the Akt/endothelial
nitric oxide synthase (eNOS) pathway. These results provided the first evidence that a CCB potentiates the vascular
protective effects of an ARB in salt-sensitive hypertension, compared with a diuretic, and provided a novel rationale
explaining the benefit of the combination therapy with an ARB and a CCB.
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Introduction
Renin-angiotensin system (RAS) blockers (angiotensin-convert-
ing enzyme inhibitors and angiotensin AT1 receptor blockers
(ARB)), as well as calcium channel blockers (CCB) or diuretics, are
recommended as the first line drugs for antihypertensive
treatment, as indicated by Western and Japanese guidelines
[1,2]. However, these antihypertensive drugs are often used in
combination in clinical practice because most hypertensive
patients do not achieve their target blood pressure by monother-
apy with each antihypertensive drug. Of the combination
therapies, a RAS blocker combined with either a CCB or a
diuretic is the main combination therapy [1,2]. However, it is
unclear which combination therapies are more effective for
vascular protection.
Excess salt intake not only causes elevated blood pressure but
also directly accelerates vascular injury, such as vascular endothe-
lial dysfunction and vascular remodeling [3,4,5]. Furthermore,
vascular injury plays a pivotal role in the development of
cardiovascular events [6,7,8,9]. However, it remains to be
determined which combination therapy more effectively protects
against vascular injury, a RAS blocker combined with a CCB or
combined with a diuretic. The present study aimed to determine
which combination therapy resulted in a greater suppression of
salt-induced vascular injury in hypertensive rats, an ARB
combined with a CCB or an ARB combined with a diuretic.
We found that a CCB enhanced the improvement of vascular
endothelial impairment and vascular remodeling by an ARB in
salt-loaded hypertensive rats more than did a diuretic, through
greater improvement of the Akt/eNOS pathway, and through
greater attenuation of oxidative stress and of the mitogen-activated
protein (MAP) kinase.
Materials and Methods
Ethics Statement
All animals experiments were approved by the Committee for
Laboratory Animal Care and Use at Kumamoto University. All
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39162experimental procedures were performed in accordance with the
Guidelines on Animal Experimentation that were released by the
Japanese Association for Laboratory Animal Science.
Experimental Animals
Male stroke-prone spontaneously hypertensive rats (SHRSP)
and control Wistar-Kyoto rats (WKY) were purchased from Japan
SLC (Shizuoka, Japan). They were fed a diet containing 8%
sodium (Na) from 11 weeks of age.
Treatment of SHRSP with Olmesartan, Azelnidipine,
Hydrochlorothiazide, and their Combination
Eleven-week-old SHRSP, fed a diet containing 8% Na, were
randomly assigned to 6 groups. They were orally administered (1)
vehicle (0.5% carboxymethyl cellulose), (2) olmesartan (1 mg/kg/
day), (3) azelnidipine (1 mg/kg/day), (4) hydrochlorothiazide
(5 mg/kg/day), (5) combined olmesartan (1 mg/kg/day) and
azelnidipine (1 mg/kg/day), or (6) combined olmesartan (1 mg/
kg/day) and hydrochlorothiazide (5 mg/kg/day) by gastric gavage
once a day for 4 weeks (from 11 to 15 weeks of age). Their blood
pressure was measured by the tail-cuff method before and 1, 2,
and 3 weeks after the start of drug treatment. After 4 weeks of the
drug treatment, SHRSP and control age-matched WKY were
perfused with phosphate-buffered saline under anesthesia with
ether; the hearts, carotid artery, and aorta were rapidly excised
from the SHRSP and WKY rats for measuring the various
parameters described below.
Arterial Ring Preparation and Tension Recording
After removal of the carotid artery from the SHRSP or WKY,
the vessel was cut into 5 mm rings with special care to preserve the
endothelium, and the rings were mounted in organ baths filled
with modified Tyrode buffer (pH 7.4; NaCl 121 mmol/L, KCl
5.9 mmol/L, CaCl2 2.5 mmol/L, MgCl2 1.2 mmol/L, NaH2PO4
1.2 mmol/L, NaHCO3 15.5 mmol/L, and D(+)-glucose
11.5 mmol/L) aerated with 95% O2 and 5% CO2 at 37uC, as
described previously [10]. The vessel rings were attached to a force
transducer, and the isometric tension was recorded on a
polygraph. A resting tension of 1 g was maintained throughout
the experiment. The aortic rings were precontracted with L-
phenylephrine (10
27 mol/L). After the plateau was attained, the
rings were exposed to increasing concentrations of acetylcholine
(Ach) (10
29 mol/L to 10
24 mol/L) or sodium nitroprusside (10
29
to 10
24 mol/L) to obtain cumulative concentration-response
curves.
Measurement of Vascular NADPH Oxidase Activity
To measure vascular NADPH oxidase activity, the excised
thoracic aorta was homogenized with an Ultraturrax T8, and the
supernatant was obtained by centrifugation for 5 minutes at
1,000 6g. Aortic NADPH oxidase activities were measured by
lucigenin chemiluminescence in the presence of 10 mM NADPH
and 10 mM lucigenin as an electron acceptor, as described
previously [11]. Chemiluminescence was recorded every 30 sec.
for 15 min. with chemiluminescence reader (BLR-201; ALOKA,
Japan). The chemiluminescence counts were corrected for the
protein concentrations. Protein concentrations were measured by
the Bradford method.
Measurement of Vascular Superoxide
Dihydroethidium (DHE) was used to evaluate the superoxide
levels in situ, as described previously [11]. The removed carotid
arteries were quickly frozen, embedded in OCT, and cryostat
sectioned (10-mm slices) directly onto chilled microscope slides.
Sections were thawed at room temperature, rehydrated with 16
phosphate-buffered saline, and incubated for 30 minutes in the
dark with the DHE (Sigma; 1 mmol/L). After washing with
phosphate-buffered saline, the DHE fluorescence was visualized
by fluorescent microscopy using an excitation wavelength of 520–
540 nm and a rhodamine emission filter. The detector and laser
settings were kept constant across all samples within individual
experiments, and the control and experimental samples were
always processed in parallel. DHE fluorescence was quantified
using Lumina Vision version 2.2, analysis software. The mean
fluorescence was quantified and expressed relative to values
obtained for the WKY rats.
Western Blot Analysis
Our detailed method has been described previously [12].
Antibodies used were as follows: anti-phospho eNOS (Ser1177)
(62000, BD Transduction Laboratories, Tokyo, Japan), anti-total
eNOS (65000, BD Transduction Laboratories, Tokyo, Japan),
anti-total Akt (62000, Cell signaling Technology Inc. Tokyo,
Japan), anti-phospho Akt (62000, Cell signaling Technology Inc.
Tokyo, Japan), anti-a-tubulin (65000, Oncogene, Tokyo, Japan),
anti-phospho-ERK (62500, Cell signaling Technology Inc.
Tokyo, Japan). The intensity of the bands was quantified using
NIH Image analysis software v1.61. In individual samples, each
value was corrected for a-tubulin.
Histological Examination
The hearts were fixed in 4% paraformaldehyde overnight.
Then, they were embedded in paraffin, sectioned into 5-mm slices,
stained with Sirius Red F3BA (0.5% in saturated aqueous picric
acid, Aldrich Chemical Company) for the assessment of collagen,
or immunostained with anti-ED-1 antibody (working dilution
1:500) for the identification of monocytes/macrophages, as
described [11]. The positive staining was detected using horse-
radish peroxidase-conjugated secondary antibodies (Nichirei,
Japan), by incubating the sections with diaminobenzidine
(DAKO). The number of ED-1-positive cells was counted in 4
horizontal LV in a blind manner and renal sections in individual
rats; and the average of ED-1 positive cell number was obtained in
individual rats [11].
Statistical Analysis
All data are presented as the mean 6 SEM. The blood pressure
data at various time points after the start of drug treatment were
analyzed by two-way analyses of variance (ANOVAs), and the
differences between each group were determined by Fisher’s
PLSD tests, using StatView for Windows (SAS Institute, Inc. Cary,
U.S.A.). For other data, statistical significance was determined
with one-way ANOVAs, followed by Fisher’s PLSD tests.
Differences were considered statistically significant at a value of
P,0.05.
Results
Effects on Blood Pressure of Salt-Loaded SHRSP
As shown in Fig. 1, olmesartan or azelnidipine monotherapy
significantly and similarly reduced the blood pressure of the salt-
loaded SHRSP throughout the drug treatment. Monotherapy with
hydrochlorothiazide significantly reduced the blood pressure of the
SHRSP, although its hypotensive effect was smaller than the effect
of monotherapy with olmesartan or azelnidipine. Combination
therapy of olmesartan with amlodipine or with hydrochlorothia-
zide reduced the blood pressure of the salt-loaded SHRSP more
Vascular Protection of a CCB and ARB Combination
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chlorothiazide. The addition of hydrochlorothiazide to olmesartan
reduced the blood pressure of the SHRSP to a similar extent to the
addition of amlodipine to olmesartan, indicating that hydrochlo-
rothiazide added to olmesartan exerted a synergistic hypotensive
effect in the salt-loaded SHRSP while azelnidipine added to
olmesartan produced an additive hypotensive effect.
Effect on Vascular Endothelial Function
As shown in Fig. 2, salt-loaded SHRSP showed markedly
impaired vascular endothelium-dependent relaxation with acetyl-
choline compared with salt-loaded WKY rats (P,0.01). Mono-
therapy with all agents significantly prevented the impairment of
vascular endothelium-dependent relaxation with acetylcholine.
Olmesartan combined with azelnidipine and hydrochlorothiazide
prevented the impairment of vascular endothelial function to a
greater extent than did monotherapy with either agent. However,
despite similar blood pressure measurements between the
azelnidipine and hydrochlorothiazide combination groups
throughout the treatment, azelnidipine enhanced the olmesar-
tan-induced improvement of vascular endothelial function in the
SHRSP to a greater extent than did hydrochlorothiazide
(P,0.01).
Vascular endothelium-independent relaxation with sodium
nitroprusside was comparable between the salt-loaded SHRSP
and WKY rats, and all monotherapies or combination therapies
did not affect it (data not shown).
Effects on Vascular Oxidative Stress
As shown in Fig. 3, vascular NADPH oxidase activity and
superoxide levels in the salt-loaded SHRSP were significantly
higher than those in the salt-loaded WKY rats. Olmesartan
combined with azelnidipine or with hydrochlorothiazide signifi-
cantly reduced vascular NADPH oxidase activity and superoxide
levels in the SHRSP, compared with any of the monotherapies.
However, olmesartan with azelnidipine attenuated vascular
NADPH oxidase activity (P,0.05) and superoxide levels
(P,0.05) to a greater extent than did olmesartan with hydrochlo-
rothiazide.
Effects on Vascular eNOS and Akt
As shown in Fig. 4 (A) and (B), the salt-loaded SHRSP showed
decreased vascular phospho-eNOS and total eNOS levels,
compared to the WKY rats. Olmesartan with azelnidipine or
with hydrochlorothiazide significantly reversed the decrease in
phospho-eNOS and total eNOS levels in the salt-loaded SHRSP.
However, olmesartan combined with azelnidipine resulted in a
greater reversal of the decrease in phospho-eNOS (P,0.01) and
total eNOS (P,0.01) than did olmesartan with hydrochlorothia-
zide.
Fig. 4 (C) and (D) showed that the salt-loaded SHRSP exhib-
ited decreased vascular phospho-Akt levels compared to the WKY
rats (P,0.01). Olmesartan or azelnidipine monotherapy signifi-
cantly reversed the decrease in phospho-Akt levels in the SHRSP,
while hydrochlorothiazide monotherapy failed to reverse it. The
combination of olmesartan with azelnidipine resulted in a greater
reversal of the decrease in phospho-Akt in the salt-loaded SHRSP,
compared to the combination of olmesartan with hydrochlorothi-
azide (P,0.05). There was no significant difference in vascular
total Akt levels among the groups.
Figure 1. Effect on blood pressure of salt-loaded SHRSP. Abbreviations used: Ve, vehicle-treated SHRSP; Ol, olmesartan-treated SHRSP; Az,
azelnidipine-treated SHRSP; Hy, hydrochlorothiazide-treated SHRSP; Ol+Az, combined olmesartan and azelnidipine-treated SHRSP; Ol+Hy, combined
olmesartan and hydrochlorothiazide-treated SHRSP; WKY, Wistar-Kyoto rats. Each value represents the mean 6 SEM (n=8 in Ve, n=7 in Ol, n=7 in
Az, n=4 in Hy, n=7 in Ol+Az, n=7 in Ol+Hy, n=8 in WKY).
doi:10.1371/journal.pone.0039162.g001
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the same as in Fig. 1. Each value represents the mean 6 SEM (n=8 in Ve, n=7 in Ol, n=7 in Az, n=4 in Hy, n=7 in Ol+Az, n=7 in Ol+Hy, n=8 in
WKY).
doi:10.1371/journal.pone.0039162.g002
Figure 3. Effect on vascular NADPH oxidase activity (A) and superoxide (B) of salt-loaded SHRSP. Abbreviations used are the same as in
Fig. 1. The upper panels in (B) indicate representative photomicrographs of carotid arterial DHE staining. Bar =200 mm. Each value represents the
mean 6 SEM ((A) n=8 in Ve, n=7 in Ol, n=7 in Az, n=4 in Hy, n=7 in Ol+Az, n=7 in Ol+Hy, n=8 in WKY; (B) n=12 in Ve, n=7 in Ol, n=7 in Az, n=7
in Hy, n=11 in Ol+Az, n=11 in Ol+Hy, n=12 in WKY).
doi:10.1371/journal.pone.0039162.g003
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As shown in Fig. 5 (A), the combination of olmesartan with
azelnidipine prevented the increase in coronary arterial thickening
in the SHRSP to a larger extent than did the combination of
olmesartan with hydrochlorothiazide (P,0.05).
Effects on Vascular MAP Kinase
As shown in Fig. 5 (B), vascular phospho-ERK levels were
higher in the salt-loaded SHRSP than in the WKY rats (P,0.01).
Olmesartan or azelnidipine alone significantly reduced the
increase in vascular phospho-ERK in the SHRSP, but hydro-
chlorothiazide alone did not significantly affect it. The combina-
tion of olmesartan and azelnidipine resulted in a greater
amelioration of the increase in vascular phospho-ERK, compared
to the combination of olmesartan and hydrochlorothiazide
(P,0.05).
Effects on Cardiac Injury and Oxidative Stress
As shown in Figs. S1 and S2, monotherapy with olmesartan and
azelnidipine similarly and significantly attenuated the increase in
left ventricular (LV) anterior wall thickness, LV interstitial fibrosis,
macrophage infiltration, NADPH oxidase activity, and superoxide
in salt-loaded SHRSP, but hydrochlorothiazide alone did not
significantly attenuate them. However, there was no significant
difference in these parameters between the olmesartan plus
azelnidipine combination group and the olmesartan plus hydro-
chlorothiazide group.
Discussion
This study produced several major findings. Azelnidipine (a
CCB) enhanced the amelioration of vascular endothelial dysfunc-
tion and vascular remodeling by olmesartan (an ARB) in salt-
loaded hypertensive rats to a greater extent than did hydrochlo-
rothiazide (a diuretic). The molecular mechanism underlying the
enhanced improvement of vascular injury by azelnidipine,
compared to hydrochlorothiazide, was associated with a greater
attenuation of vascular NADPH oxidase-mediated superoxide and
MAP kinase activation, and an increase in phosphorylation of Akt
and eNOS by azelnidipine, compared to hydrochlorothiazide.
Thus, our present work provided the molecular evidence for the
superiority of a combination therapy of an ARB with a CCB over
a combination of an ARB with a diuretic, and the results also
provided an explanation for the clinical evidence obtained from
the ACCOMPLISH trial on high-risk hypertensive patients [13].
Salt plays an important role in the progression of cardiovascular
events as well as the pathogenesis of hypertension [3,4,5].
Epidemiologic studies showed that high sodium intake is an
independent risk factor for cardiovascular disease [14]. Further-
more, cardiovascular events are reported to occur more frequently
in patients with salt-sensitive hypertension compared with those
Figure 4. Effect on vascular phospho-eNOS (p-eNOS) (A), total eNOS (t-eNOS) (B), phospho-Akt (p-Akt) (C), and total Akt (t-Akt) (D)
of salt-loaded SHRSP. Abbreviations used are the same as in Fig. 1. The upper panels in (A), (B), (C), and (D) indicate representative western blots in
each group. Each value represents the mean 6 SEM (n=4 in each group).
doi:10.1371/journal.pone.0039162.g004
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the development of vascular endothelial dysfunction and athero-
sclerosis, which are responsible for cardiovascular events and
death [3,4,5]. Therefore, it is a clinically important issue to define
an appropriate therapeutic strategy for salt-induced cardiovascular
injury. Although the combination therapy of a RAS blocker with a
CCB or with a diuretic is regarded as the main therapeutic
strategy for hypertension [1,2], it is unknown which therapeutic
strategy is superior in preventing salt-induced vascular injury, a
RAS blocker with a CCB or with a diuretic. In the current study,
of note, despite comparable blood pressure lowering between the
two combination therapies, a CCB (azelnidipine) enhanced the
amelioration of vascular endothelial dysfunction and vascular
remodeling by an ARB (olmesartan) in salt-loaded hypertensive
rats, compared to a diuretic, indicating that the greater
enhancement by a CCB, compared to a diuretic, of ARB-induced
vascular protection was attributed to blood pressure-independent
mechanisms. To elucidate the molecular mechanism responsible
for superiority of a CCB over a diuretic in this study, we examined
the comparative effect of a CCB and a diuretic on vascular
oxidative stress, the Akt/eNOS pathway, and MAP kinase in salt-
loaded hypertensive rats. Superoxide and Akt/eNOS pathway-
mediated NO play a counterregulatory role in vascular endothelial
function [6,7,8,9]. Vascular endothelial dysfunction is mainly
caused by the reduction of NO bioavailability. Superoxide, the
initial product of reactive oxygen species (ROS), scavenges NO,
which leads to a decrease in NO bioavailability and to the
subsequent impairment of vascular endothelial function. In this
work, we found that salt loading significantly impaired vascular
endothelial function (Ach-induced vasodilation) in SHRSP, which
was associated with increased vascular superoxide and the
decreased phospho-Akt and phospho-eNOS levels. Of note,
despite comparable blood pressure lowering effects between the
two combination therapies, a CCB added to an ARB prevented
salt-induced vascular endothelial impairment in SHRSP to a
greater extent than did a diuretic added to an ARB. Furthermore,
an ARB combined with a CCB ameliorated the increase in
superoxide and the decrease in phospho-Akt and phospho-eNOS
more potently than did an ARB combined with a diuretic. These
results showed that an ARB combined with a CCB protects
against salt-induced vascular endothelial impairment more than
did an ARB with a diuretic, through greater amelioration of both
oxidative stress and the impaired Akt/eNOS pathway. Being
consistent with our previous report on Dahl salt-sensitive
hypertensive rats [10], salt loading significantly decreased vascular
total eNOS as well as phospho-eNOS in SHRSP. An ARB plus a
CCB combination ameliorated the decrease in total-eNOS more
than an ARB plus a diuretic. These results suggest that the
increase in phospho-eNOS by an ARB plus a CCB combination
might be partially attributed to the increase in total-eNOS by this
combination therapy, although further study is needed to elucidate
our assumption.
Furthermore, we also found that an ARB combined with a CCB
attenuated salt-induced coronary arterial thickening more than did
an ARB with a diuretic, a finding which was accompanied by a
greater attenuation of vascular ERK phosphorylation by an ARB
with a CCB. Taken together with the fact that ERK activation
participates in the acceleration of vascular remodeling through
smooth muscle cell proliferation and migration [15,16,17], the
greater inhibition of vascular remodeling by an ARB combined
with a CCB than with a diuretic seems to be at least partially
mediated by a greater inhibition of ERK activation by an ARB
combined with a CCB.
Figure 5. Effect on coronary arterial thickening (A) and vascular phospho-ERK (B) of salt-loaded SHRSP. Abbreviations used are the
same as in Fig. 1. The upper panels in (A) indicate representative photomicrographs of the coronary artery in Sirius red-stained cardiac sections from
each group. Each value represents the mean 6 SEM (n=12 in Ve, n=7 in Ol, n=7 in Az, n=7 in Hy, n=11 in Ol+Az, n=11 in Ol+Hy, n=12 in WKY).
The upper panels in (B) indicate representative western blots in each group. Each value represents the mean 6 SEM (n=4 in each group). The value
of phospho p44/42 ERK corrected for total p44/42 ERK provided the same results as the value of phospho p44/42 ERK corrected for tubulin.
doi:10.1371/journal.pone.0039162.g005
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CCB enhanced ARB-induced protection against salt-induced
vascular injury in hypertensive rats more potently than did a
diuretic. Therefore, our present experimental findings provide a
novel insight into a therapeutic strategy for salt-induced vascular
injury as well as an explanation for the clinical evidence obtained
by the ACCOMPLISH trial [13], in which a RAS blocker
combined with a CCB, compared to a RAS blocker combined
with a diuretic, prevented more cardiovascular events in high-risk
hypertensive patients. Furthermore, vascular endothelial dysfunc-
tion and vascular structural remodeling play a causative role in the
development of hypertensive cardiovascular events. Therefore, the
protective effects of an ARB plus a CCB combination against
vascular endothelial dysfunction and remodeling in salt-loaded
hypertensive rats seem to confer the benefit in prevention of
cardiovascular events. However, extrapolation of our experimental
findings to clinical situation should be made with caution.
Supporting Information
Figure S1 Effect on left ventricular (LV) anterior wall thickness
(A), LV interstitial fibrosis (B), and macrophage infiltration of salt-
loaded SHRSP. Abbreviations used: Ve, vehicle-treated SHRSP;
Ol, olmesartan-treated SHRSP; Az, azelnidipine-treated SHRSP;
Hy, hydrochlorothiazide-treated SHRSP; Ol+Az, combined
olmesartan and azelnidipine-treated SHRSP; Ol+Hy, combined
olmesartan and hydrochlorothiazide-treated SHRSP; WKY,
Wistar-Kyoto rats. The upper panels in (B) and (C) indicate
representative photomicrographs of Sirius red-stained cardiac
sections and ED-1-immunostained cardiac sections, respectively,
from each group. Each value represents mean 6 SEM ((A) n=8 in
Ve, n=7 in Ol, n=7 in Az, n=4 in Hy, n=7 in Ol+Az, n=7 in
Ol+Hy, n=8 in WKY; (B) (n=8 in Ve, n=7 in Ol, n=7 in Az,
n=4inHy,n=7inOl+Az, n=4 in Ol+Hy, n=8 in WKY). NS,
not significant.
(TIF)
Figure S2 Effect on LV NADPH oxidase activity and
superoxide of salt-loaded SHRSP. Abbreviations used are the
same as in Fig. S1. The upper panels in (B) indicate representative
photomicrographs of cardiac DHE staining from each group.
Bar=100 mm. Each value represents the mean 6 SEM (n=8 in
Ve, n=7 in Ol, n=7 in Az, n=4 in Hy, n=7 in Ol+Az, n=7 in
Ol+Hy, n=8 in WKY).
(TIF)
Author Contributions
Conceived and designed the experiments: EY SKM. Performed the
experiments: EY SKM KK YFD NK KT DS TK OY HO. Analyzed the
data: EY SKM. Contributed reagents/materials/analysis tools: EY SKM.
Wrote the paper: EY SKM.
References
1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) 2007
Guidelines for the management of arterial hypertension: The Task Force for the
Management of Arterial Hypertension of the European Society of Hypertension
(ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462–
1536.
2. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, et al. (2009) The
Japanese Society of Hypertension Guidelines for the Management of
Hypertension (JSH 2009). Hypertens Res 32: 3–107.
3. Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA (2005) Links
between dietary salt intake, renal salt handling, blood pressure, and
cardiovascular diseases. Physiol Rev 85: 679–715.
4. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, et al. (1997) Sodium
sensitivity and cardiovascular events in patients with essential hypertension.
Lancet 350: 1734–1737.
5. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M (2001) Salt
sensitivity, pulse pressure, and death in normal and hypertensive humans.
Hypertension 37: 429–432.
6. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases:
the role of oxidant stress. Circ Res 87: 840–844.
7. Forstermann U, Munzel T (2006) Endothelial nitric oxide synthase in vascular
disease: from marvel to menace. Circulation 113: 1708–1714.
8. Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in
cardiovascular biology and disease. Circ Res 86: 494–501.
9. Mueller CF, Laude K, McNally JS, Harrison DG (2005) ATVB in focus: redox
mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 25: 274–278.
10. Yamamoto E, Kataoka K, Shintaku H, Yamashita T, Tokutomi Y, et al. (2007)
Novel mechanism and role of angiotensin II induced vascular endothelial injury
in hypertensive diastolic heart failure. Arterioscler Thromb Vasc Biol 27: 2569–
2575.
11. Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, et al. (2007)
Role of xanthine oxidoreductase in the reversal of diastolic heart failure by
candesartan in the salt-sensitive hypertensive rat. Hypertension 50: 657–662.
12. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, et al. (2008)
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are
enhanced by combination with candesartan. Hypertension 51: 296–301.
13. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, et al. (2008) Benazepril
plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med 359: 2417–2428.
14. Tuomilehto J, Jousilahti P, Rastenyte D, Moltchanov V, Tanskanen A, et al.
(2001) Urinary sodium excretion and cardiovascular mortality in Finland: a
prospective study. Lancet 357: 848–851.
15. Force T, Pombo CM, Avruch JA, Bonventre JV, Kyriakis JM (1996) Stress-
activated protein kinases in cardiovascular disease. Circ Res 78: 947–953.
16. Gerthoffer WT (2007) Mechanisms of vascular smooth muscle cell migration.
Circ Res 100: 607–621.
17. Muslin AJ (2008) MAPK signalling in cardiovascular health and disease:
molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115: 203–218.
Vascular Protection of a CCB and ARB Combination
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39162